Acadia Healthcare Company Inc vs IDEXX Laboratories, Inc. — how do they compare? Acadia Healthcare Company Inc trades at $31.88 (market cap $2.90B), while IDEXX Laboratories, Inc. trades at $571.33 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 15.9× Acadia Healthcare Company Inc's market cap, and Acadia Healthcare Company Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| ACHC | IDXX | |
|---|---|---|
Market Cap | $2.90B | $46.22B |
Sector | Health | Health |
52-Week High | $35.61 | $766.68 |
52-Week Low | $11.68 | $526.44 |
Enterprise Value | $5.29B | $47.12B |
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.85, up 0.22% today, with a neutral technical signal and bullish moving averages. The company reported Q2 2026 EPS of $0.38, beating estimates, but maintains negative net income margins near -33%. Revenue is stable at $3.3B, while analyst consensus is a Buy with a $36 price target. Recent news highlights ongoing litigation and operational progress.
Outlook is mixed: strong analyst support and earnings beats suggest upside, but profitability challenges and legal investigations pose significant risks. The stock's valuation appears reasonable with a P/E of 19.82, yet negative ROE and net income require careful monitoring for turnaround execution.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Trailing returns across standard periods
Latest headlines on both assets
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →